/CYT

CYT Stock - Cyteir Therapeutics, Inc.

Q: What is the analyst price target for CYT?

Analyst price target information is not currently available for CYT.

Q: What is CYT's market cap?

Market capitalization information is not currently available for CYT.

Healthcare|Biotechnology|NASDAQ

$3.02-2.27%

$0.07 (-2.27%) • Mar 15

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

100

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+-33.8%upside

Target: $2.00

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for CYT

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2019

FY2020

FY2021

FY2022

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta0.10

52W High$3.19

52W Low$1.65

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2022	FY2021	FY2020	FY2019
Revenue	N/A	N/A	N/A	$8,000
Gross Profit	$-1,375,000	$-479,000	$-351,000	$-4,689
Gross Margin	N/A	N/A	N/A	-58.6%
Operating Income	$-48,170,000	$-42,259,000	$-20,943,000	$-16,105,000
Net Income	$-43,952,000	$-41,647,000	$-20,823,000	$-15,044,000
Net Margin	N/A	N/A	N/A	-188050.0%
EPS	$-1.25	$-1.18	$-0.87	$-0.77

Company Overview

Cyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the next-generation of precision oncology medicines. Its lead product CYT-0851, a novel, oral, once-daily, small molecule drug candidate that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for combination therapy in solid tumors and hematologic malignancies. The company is also developing CYT-1853, which is in preclinical trials for solid tumors and hematologic malignancies. The company was incorporated in 2012 and is based in Lexington, Massachusetts.

Visit Website

Earnings History & Surprises

CYT

Beat Rate

60%

Last 10 quarters

Avg Surprise

-16.8%

EPS vs Estimate

Beats / Misses

6/4

Last 12 quarters

Latest EPS

$-0.25

Q1 2024

EPS Surprise History

Q2 22

-2.6%

$-0.40vs$-0.39

Q3 22

+22.7%

$-0.34vs$-0.44

Q4 22

+24.4%

$-0.31vs$-0.41

Q1 23

+26.5%

$-0.25vs$-0.34

Q2 23

-29.6%

$-0.35vs$-0.27

Q3 23

+25.0%

$-0.24vs$-0.32

Q4 23

No data

Q1 24

-25.0%

$-0.25vs$-0.20

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q1 2024	Mar 28, 2024	$-0.20	$-0.25	-25.0%	✗ MISS
Q4 2023	Nov 6, 2023	—	$-0.10	—	—
Q3 2023	Aug 7, 2023	$-0.32	$-0.24	+25.0%	✓ BEAT
Q2 2023	May 10, 2023	$-0.27	$-0.35	-29.6%	✗ MISS
Q1 2023	Mar 23, 2023	$-0.34	$-0.25	+26.5%	✓ BEAT
Q4 2022	Nov 7, 2022	$-0.41	$-0.31	+24.4%	✓ BEAT
Q3 2022	Aug 8, 2022	$-0.44	$-0.34	+22.7%	✓ BEAT
Q2 2022	May 5, 2022	$-0.39	$-0.40	-2.6%	✗ MISS
Q1 2022	Mar 16, 2022	$-0.39	$-0.34	+12.8%	✓ BEAT
Q4 2021	Nov 12, 2021	$-0.36	$-0.33	+8.3%	✓ BEAT
Q3 2021	Aug 9, 2021	$-1.46	$-4.83	-230.8%	✗ MISS
Q1 2021	Mar 31, 2021	—	$-0.21	—	—
Q4 2020	Dec 31, 2020	—	$-0.22	—	—
Q3 2020	Sep 30, 2020	—	$-0.21	—	—
Q2 2020	Jun 30, 2020	—	$-0.19	—	—
Q1 2020	Mar 31, 2020	—	$-0.25	—	—

Frequently Asked Questions about CYT

What is CYT's current stock price?

Cyteir Therapeutics, Inc. (CYT) is currently trading at $3.02 per share. The stock has moved -2.27% today.

What is the analyst price target for CYT?

The average analyst price target for CYT is $2.00, based on 1 analyst.

What sector is Cyteir Therapeutics, Inc. in?

Cyteir Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.

What is CYT's market cap?

Cyteir Therapeutics, Inc. has a market capitalization of $0.11 billion, making it a small-cap company.

Does CYT pay dividends?

No, Cyteir Therapeutics, Inc. does not currently pay a dividend to shareholders.